3-(羟甲基)-4-甲基吡咯烷-1-羧酸反丁酯 | 1349715-96-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 3-(羟甲基)-4-甲基吡咯烷-1-羧酸反丁酯
• 英文名称: tert-butyl (3R,4R)-3-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate
• CAS: 1349715-96-3
• 化学式: C₁₁H₂₁NO₃
• 分子量: 215.293
• InChiKey: QNVPXIMDUBAIPY-DTWKUNHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(羟甲基)-4-甲基吡咯烷-1-羧酸反丁酯 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.5h， 以79%的产率得到trans-3-formyl-4-methylpyrrolidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Diastereodivergent Access to Syn and Anti 3,4-Substituted β-Fluoropyrrolidines: Enhancing or Reversing Substrate Preference

  摘要：

  A practical diastereodivergent access to beta-fluoropyrrolidines with two adjacent stereocenters has been demonstrated, by either enhancing or completely reversing the substrate control, in the diastereoselective fluorination of a series of diverse pyrrolidinyl carbaldehydes using organocatalysis. Furthermore, enamine catalysis has been successfully utilized for kinetic resolution, obtaining a fluorinated beta-prolinol analogue with two adjacent tetrasubstituted chiral centers in 95% ee from a racemic substrate.

  DOI：

  10.1021/acs.orglett.6b00293
• 作为产物：
  描述：

  trans-(1-benzyl-4-methylpyrrolidin-3-yl)methanol 在 sodium carbonate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 13.5h， 生成 3-(羟甲基)-4-甲基吡咯烷-1-羧酸反丁酯
  参考文献：
  名称：

  Diastereodivergent Access to Syn and Anti 3,4-Substituted β-Fluoropyrrolidines: Enhancing or Reversing Substrate Preference

  摘要：

  A practical diastereodivergent access to beta-fluoropyrrolidines with two adjacent stereocenters has been demonstrated, by either enhancing or completely reversing the substrate control, in the diastereoselective fluorination of a series of diverse pyrrolidinyl carbaldehydes using organocatalysis. Furthermore, enamine catalysis has been successfully utilized for kinetic resolution, obtaining a fluorinated beta-prolinol analogue with two adjacent tetrasubstituted chiral centers in 95% ee from a racemic substrate.

  DOI：

  10.1021/acs.orglett.6b00293

文献信息

• PYRROLOPYRIMIDINE AND PURINE DERIVATIVES
  申请人：Cheng Hengmiao

  公开号：US20130079324A1

  公开（公告）日：2013-03-28

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m在此定义。这些新颖的吡咯嘧啶和嘌呤衍生物在哺乳动物中治疗异常细胞生长，如癌症方面具有用处。另外，本发明还涉及含有这些化合物的药物组合物，以及在哺乳动物中治疗异常细胞生长的方法。
• US9040547B2
  申请人：——

  公开号：US9040547B2

  公开（公告）日：2015-05-26
• [EN] APOL1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS D'APOL1 ET MÉTHODES D'UTILISATION
  申请人：[en]MAZE THERAPEUTICS, INC.

  公开号：WO2022178315A1

  公开（公告）日：2022-08-25

  Provided herein are compounds of formula (A'): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, X3, X4, Ra, Rb, Rc, L, Q, and Y are as defined herein. Also provided are methods of inhibiting APOL1 and methods of preparing compounds of formula (A'). Also provided are methods of inhibiting APOL1 and methods of treating an APOL1 -mediated disease, disorder, or condition in an individual.